Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Cardio-ankle vascular index for predicting cardiovascular morbimortality and determinants for its progression in the prospective advanced approach to arterial stiffness (TRIPLE-A-Stiffness) study

M. Bäck, J. Topouchian, C. Labat, S. Gautier, J. Blacher, M. Cwynar, A. de la Sierra, D. Pall, K. Duarte, F. Fantin, K. Farkas, L. Garcia-Ortiz, Z. Hakobyan, P. Jankowski, A. Jelakovic, M. Kotsani, A. Konradi, O. Mikhailova, I. Mintale, O....

. 2024 ; 103 (-) : 105107. [pub] 20240417

Jazyk angličtina Země Nizozemsko

Typ dokumentu časopisecké články, multicentrická studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc24014076

BACKGROUND: The cardio-ankle vascular index (CAVI) measure of arterial stiffness is associated with prevalent cardiovascular risk factors, while its predictive value for cardiovascular events remains to be established. The aim was to determine associations of CAVI with cardiovascular morbimortality (primary outcome) and all-cause mortality (secondary outcome), and to establish the determinants of CAVI progression. METHODS: TRIPLE-A-Stiffness, an international multicentre prospective longitudinal study, enrolled >2000 subjects ≥40 years old at 32 centres from 18 European countries. Of these, 1250 subjects (55% women) were followed for a median of 3.82 (2.81-4.69) years. FINDINGS: Unadjusted cumulative incidence rates of outcomes according to CAVI stratification were higher in highest stratum (CAVI > 9). Cox regression with adjustment for age, sex, and cardiovascular risk factors revealed that CAVI was associated with increased cardiovascular morbimortality (HR 1.25 per 1 increase; 95% confidence interval, CI: 1.03-1.51) and all-cause mortality (HR 1.37 per 1 increase; 95% CI: 1.10-1.70) risk in subjects ≥60 years. In ROC analyses, CAVI optimal threshold was 9.25 (c-index 0.598; 0.542-0.654) and 8.30 (c-index 0.565; 0.512-0.618) in subjects ≥ or <60 years, respectively, to predict increased CV morbimortality. Finally, age, mean arterial blood pressure, anti-diabetic and lipid-lowering treatment were independent predictors of yearly CAVI progression adjusted for baseline CAVI. INTERPRETATION: The present study identified additional value for CAVI to predict outcomes after adjustment for CV risk factors, in particular for subjects ≥60 years. CAVI progression may represent a modifiable risk factor by treatments. FUNDING: International Society of Vascular Health (ISVH) and Fukuda Denshi, Japan.

Almazov Federal Medical Research Centre St Petersburg Russia

Cardiometabolic Centre Dept of Angiology Szent Imre University Teaching Hospital Budapest Hungary

Department of Internal Medicine and Geriatric Cardiology Centre of Postgraduate Medical Education Warsaw Poland

Department of Internal Medicine and Gerontology Jagiellonian University Medical College Kraków Poland

Department of Internal Medicine Hospital Mutua Terrassa University of Barcelona Terrassa Spain

Department of Medical Clinical Pharmacology University of Debrecen Hungary

Department of Medicine Section of Geriatric Medicine University of Verona Italy

Department of Medicine Solna Karolinska Institutet and Department of Cardiology Karolinska University Hospital Stockholm Sweden

Department of Nephrology Hypertension Dialysis and Transplantation University Hospital Centre Zagreb Croatia

Department of Preventive Cardiology Institute for Clinical and Experimental Medicine Prague Czech Republic

Foundation Medical Research Institutes Paris France

FSBI Chazov National Medical Research Centre of Cardiology of the Ministery of Health of the Russian Federation Moscow Russia

Government Institution L T Malaya Therapy Institute of the National Academy of Medical Sciences of Ukraine Kharkov Ukraine

Inserm U1116 Nancy France

Institut Universitari d'Investigació en Atenció Primària Jordi Gol Department of Medical Sciences University of Girona Primary Care Services Biomedical Research Institute Institut Català de la Salut Girona Spain

Institute of Cardiology Centre of Preventive Cardiology Yerevan Armenia

Institute of Cardiology Kiev Ukraine

Medical Faculty University of Belgrade and Cardiovascular Institute Dedinje Belgrade Serbia

P Stradins University Hospital Cardiology Centre Riga Latvia

Paris Descartes University AP HP Diagnosis and Therapeutic Center Hôtel Dieu Paris France

Primary Care Research Unit of Salamanca Department of Biomedical and Diagnostic Sciences University of Salamanca Salamanca Spain

Scientific and Research Institute of Cardiology and Internal Diseases Almaty Kazakhstan

Université de Lorraine CHRU Nancy University Hospital of Nancy France

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24014076
003      
CZ-PrNML
005      
20240905134308.0
007      
ta
008      
240725e20240417ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ebiom.2024.105107 $2 doi
035    __
$a (PubMed)38632024
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Bäck, Magnus $u Department of Medicine Solna, Karolinska Institutet and Department of Cardiology Karolinska University Hospital, Stockholm, Sweden; Inserm U1116, Nancy, France; Université de Lorraine, CHRU Nancy, University Hospital of Nancy, France. Electronic address: Magnus.Back@ki.se
245    10
$a Cardio-ankle vascular index for predicting cardiovascular morbimortality and determinants for its progression in the prospective advanced approach to arterial stiffness (TRIPLE-A-Stiffness) study / $c M. Bäck, J. Topouchian, C. Labat, S. Gautier, J. Blacher, M. Cwynar, A. de la Sierra, D. Pall, K. Duarte, F. Fantin, K. Farkas, L. Garcia-Ortiz, Z. Hakobyan, P. Jankowski, A. Jelakovic, M. Kotsani, A. Konradi, O. Mikhailova, I. Mintale, O. Plunde, R. Ramos, A. Rogoza, Y. Sirenko, N. Tasic, I. Rudyk, S. Urazalina, P. Wohlfahrt, P. Zelveian, R. Asmar, A. Benetos
520    9_
$a BACKGROUND: The cardio-ankle vascular index (CAVI) measure of arterial stiffness is associated with prevalent cardiovascular risk factors, while its predictive value for cardiovascular events remains to be established. The aim was to determine associations of CAVI with cardiovascular morbimortality (primary outcome) and all-cause mortality (secondary outcome), and to establish the determinants of CAVI progression. METHODS: TRIPLE-A-Stiffness, an international multicentre prospective longitudinal study, enrolled >2000 subjects ≥40 years old at 32 centres from 18 European countries. Of these, 1250 subjects (55% women) were followed for a median of 3.82 (2.81-4.69) years. FINDINGS: Unadjusted cumulative incidence rates of outcomes according to CAVI stratification were higher in highest stratum (CAVI > 9). Cox regression with adjustment for age, sex, and cardiovascular risk factors revealed that CAVI was associated with increased cardiovascular morbimortality (HR 1.25 per 1 increase; 95% confidence interval, CI: 1.03-1.51) and all-cause mortality (HR 1.37 per 1 increase; 95% CI: 1.10-1.70) risk in subjects ≥60 years. In ROC analyses, CAVI optimal threshold was 9.25 (c-index 0.598; 0.542-0.654) and 8.30 (c-index 0.565; 0.512-0.618) in subjects ≥ or <60 years, respectively, to predict increased CV morbimortality. Finally, age, mean arterial blood pressure, anti-diabetic and lipid-lowering treatment were independent predictors of yearly CAVI progression adjusted for baseline CAVI. INTERPRETATION: The present study identified additional value for CAVI to predict outcomes after adjustment for CV risk factors, in particular for subjects ≥60 years. CAVI progression may represent a modifiable risk factor by treatments. FUNDING: International Society of Vascular Health (ISVH) and Fukuda Denshi, Japan.
650    _2
$a lidé $7 D006801
650    _2
$a ženské pohlaví $7 D005260
650    12
$a tuhost cévní stěny $7 D059289
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    12
$a cévní index srdce-kotník $7 D000080308
650    _2
$a senioři $7 D000368
650    12
$a kardiovaskulární nemoci $x mortalita $x diagnóza $x etiologie $7 D002318
650    _2
$a prospektivní studie $7 D011446
650    _2
$a progrese nemoci $7 D018450
650    _2
$a rizikové faktory $7 D012307
650    _2
$a ROC křivka $7 D012372
650    _2
$a dospělí $7 D000328
650    _2
$a longitudinální studie $7 D008137
650    _2
$a prognóza $7 D011379
650    _2
$a rizikové faktory kardiovaskulárních chorob $7 D000082742
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
700    1_
$a Topouchian, Jirar $u Paris-Descartes University, AP-HP, Diagnosis and Therapeutic Center, Hôtel Dieu, Paris, France
700    1_
$a Labat, Carlos $u Inserm U1116, Nancy, France
700    1_
$a Gautier, Sylvie $u Université de Lorraine, CHRU Nancy, University Hospital of Nancy, France
700    1_
$a Blacher, Jacques $u Paris-Descartes University, AP-HP, Diagnosis and Therapeutic Center, Hôtel Dieu, Paris, France
700    1_
$a Cwynar, Marcin $u Department of Internal Medicine and Gerontology, Jagiellonian University Medical College, Kraków, Poland
700    1_
$a de la Sierra, Alejandro $u Department of Internal Medicine, Hospital Mutua Terrassa, University of Barcelona, Terrassa, Spain
700    1_
$a Pall, Denes $u Department of Medical Clinical Pharmacology, University of Debrecen, Hungary
700    1_
$a Duarte, Kevin $u Université de Lorraine, CHRU Nancy, University Hospital of Nancy, France
700    1_
$a Fantin, Francesco $u Department of Medicine, Section of Geriatric Medicine, University of Verona, Italy
700    1_
$a Farkas, Katalin $u Cardiometabolic Centre, Dept. of Angiology, Szent Imre University Teaching Hospital, Budapest, Hungary
700    1_
$a Garcia-Ortiz, Luis $u Primary Care Research Unit of Salamanca (APISAL), Biomedical Research Institute of Salamanca (IBSAL), Department of Biomedical and Diagnostic Sciences, University of Salamanca, Salamanca, Spain
700    1_
$a Hakobyan, Zoya $u Institute of Cardiology, Centre of Preventive Cardiology, Yerevan, Armenia
700    1_
$a Jankowski, Piotr $u Department of Internal Medicine and Geriatric Cardiology, Centre of Postgraduate Medical Education, Warsaw, Poland
700    1_
$a Jelakovic, Ana $u Department of Nephrology, Hypertension, Dialysis and Transplantation, University Hospital Centre, Zagreb, Croatia
700    1_
$a Kotsani, Marina $u Université de Lorraine, CHRU Nancy, University Hospital of Nancy, France
700    1_
$a Konradi, Alexandra $u Almazov Federal Medical Research Centre, St-Petersburg, Russia
700    1_
$a Mikhailova, Oksana $u FSBI "Chazov National Medical Research Centre of Cardiology" of the Ministery of Health of the Russian Federation, Moscow, Russia
700    1_
$a Mintale, Iveta $u P. Stradins University Hospital, Cardiology Centre, Riga, Latvia
700    1_
$a Plunde, Oscar $u Department of Medicine Solna, Karolinska Institutet and Department of Cardiology Karolinska University Hospital, Stockholm, Sweden
700    1_
$a Ramos, Rafael $u Institut Universitari d'Investigació en Atenció Primària Jordi Gol, Department of Medical Sciences, University of Girona, Primary Care Services, Biomedical Research Institute, Institut Català de la Salut, Girona, Spain
700    1_
$a Rogoza, Anatoly $u FSBI "Chazov National Medical Research Centre of Cardiology" of the Ministery of Health of the Russian Federation, Moscow, Russia
700    1_
$a Sirenko, Yuriy $u Institute of Cardiology, Kiev, Ukraine
700    1_
$a Tasic, Nebojsa $u Medical Faculty, University of Belgrade and Cardiovascular Institute, Dedinje, Belgrade, Serbia
700    1_
$a Rudyk, Iurii $u Government Institution, L.T. Malaya Therapy Institute of the National Academy of Medical Sciences of Ukraine, Kharkov, Ukraine
700    1_
$a Urazalina, Saule $u Scientific and Research Institute of Cardiology and Internal Diseases, Almaty, Kazakhstan
700    1_
$a Wohlfahrt, Peter $u Department of Preventive Cardiology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic
700    1_
$a Zelveian, Parounak $u Institute of Cardiology, Centre of Preventive Cardiology, Yerevan, Armenia
700    1_
$a Asmar, Roland $u Foundation-Medical Research Institutes, Paris, France
700    1_
$a Benetos, Athanase $u Inserm U1116, Nancy, France; Université de Lorraine, CHRU Nancy, University Hospital of Nancy, France
773    0_
$w MED00190061 $t EBioMedicine $x 2352-3964 $g Roč. 103 (20240417), s. 105107
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38632024 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240725 $b ABA008
991    __
$a 20240905134302 $b ABA008
999    __
$a ok $b bmc $g 2143698 $s 1225942
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 103 $c - $d 105107 $e 20240417 $i 2352-3964 $m EBioMedicine $n EBioMedicine $x MED00190061
LZP    __
$a Pubmed-20240725

Najít záznam

Citační ukazatele

Možnosti archivace